What Is Immuneering Corporation (IMRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Immuneering Corporation's intrinsic value is estimated at a composite fair value of $3.81. Trading at $5.16, the stock is approaching fair value or slight overvaluation (implied return of -26.1%), as 5 of 7 models suggest limited further upside. Model dispersion is worth noting: Sentiment SOTP targets $6.10 (+18.3%), versus Bayesian DCF at $2.15 (-58.3%). This +76.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About IMRX?
7 of 13 models are currently active for IMRX. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates IMRX's intrinsic value at $2.15, implying -58.3% downside from the current price. See which stocks rank higher →
How Does IMRX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IMRX ranks #236 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Immuneering Corporation, metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.
Is IMRX a Value Trap?
CirclFi's Value Trap algorithm assigns IMRX a score of 45/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Immuneering Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Immuneering Corporation scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +76.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IMRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IMRX's 7 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad